ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2251

Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer

Michelle Nguyen1, Aaron Baraff2, Alexandra Schmidt2, Alexander Peterson2, Aliyah Pabani3, Nicholas Smith1, Shelly Gray1, Jose Garcia4, Noel Weiss1 and Namrata Singh5, 1University of Washington, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3Johns Hopkins, Washington, DC, 4VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, 5University of Washington, Bellevue, WA

Meeting: ACR Convergence 2025

Keywords: Comorbidity, Mortality, Oncology, rheumatoid arthritis, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA and overall survival in those who develop lung cancer has not been well characterized. The objective of this study was to evaluate the relationship between RA and overall survival among older adults diagnosed with lung cancer.

Methods: Data spanning 2005-2023 was obtained from the Veteran’s Health Administration’s (VHA) electronic medical records, commonly referred to as the Corporate Data Warehouse (CDW). Patients with lung cancer were identified from the Oncology Raw domain, which contains records of patients diagnosed with cancer and associated information, such as cancer stage and treatments. The cohort included patients aged 50 years or older at the time of lung cancer diagnosis. Pre-existing rheumatoid arthritis (RA) was identified based on the presence of ≥ 2 ICD-9 or ICD-10 codes for RA, 1 to 365 days apart, prior to the lung cancer diagnosis. The association between RA and all-cause mortality was evaluated using Cox proportional hazards regression models, adjusting for demographic characteristics, smoking status, comorbid conditions, prior history of malignancy, and cancer stage at diagnosis.

Results: Among 128,291 patients with lung cancer, 2,864 (2.2%) had pre-existing RA. The cohort was predominantly male (97.4%), White (75.4%) and current smokers (52%) (Table 1). During follow-up, mortality rates were 370.4 and 403.0 per 1,000 person-years in the non-RA and RA groups, respectively. After adjusting for demographics, smoking status, comorbidities, prior malignancy, and lung cancer stage, RA was associated with increased all-cause mortality (adjusted hazard ratio 1.09; 95% CI: 1.05-1.14) (Table 2).

Conclusion: In this study using national VA data, pre-existing RA was associated with a modest but statistically significant increase in all-cause mortality. After adjusting for key clinical and demographic factors, patients with RA had a 9% higher risk of death compared to those without RA. These findings suggest that RA may independently contribute to poorer survival in patients with lung cancer, highlighting the need for integrative care strategies that address both oncologic and rheumatologic complexities in this high-risk population.

Supporting image 1Table 1: Baseline Characteristics of Patients with RA and Lung Cancer

Supporting image 2Table 2: Age-Adjusted Mortality Rates and Multivariable Adjusted Hazard Ratio


Disclosures: M. Nguyen: None; A. Baraff: None; A. Schmidt: None; A. Peterson: None; A. Pabani: None; N. Smith: None; S. Gray: None; J. Garcia: Aveo Oncology, 2, Catalym, 2, Pfizer, 5; N. Weiss: None; N. Singh: None.

To cite this abstract in AMA style:

Nguyen M, Baraff A, Schmidt A, Peterson A, Pabani A, Smith N, Gray S, Garcia J, Weiss N, Singh N. Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/dual-diagnoses-diminished-survival-association-between-rheumatoid-arthritis-and-survival-among-older-adults-with-lung-cancer/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dual-diagnoses-diminished-survival-association-between-rheumatoid-arthritis-and-survival-among-older-adults-with-lung-cancer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology